人三碘甲腺乙酸跨膜转运体的鉴定
研究通过全基因组RNAi筛选HepG2细胞,鉴定SLC22A9/OAT7和SLC29A2/ENT2介导三碘甲腺乙酸(TRIAC)的细胞摄取,ABCD1为TRIAC外排泵;TRIAC转运体表达模式有助于解释其疗效差异。
要点
- SLC22A9编码的OAT7和SLC29A2编码的ENT2介导TRIAC的细胞摄取。
- ABCD1被鉴定为TRIAC的外排泵。
- TRIAC转运体表达模式可能有助于解释TRIAC在某些细胞或器官中无效的原因。
核心结论
- 鉴定出SLC22A9/OAT7和SLC29A2/ENT2介导TRIAC细胞摄取,ABCD1为TRIAC外排泵;TRIAC转运体表达知识可能有助于解释TRIAC效应及在不表达适当转运体的细胞或器官中可能不显示理想效果的原因。
研究设计与样本
- 在稳定表达T3受体依赖性荧光素酶报告基因的HepG2细胞中进行全基因组RNAi筛选,并通过反筛和比较TRIAC与T3的细胞反应验证候选基因。
- 将鉴定出的TRIAC偏好性转运体C端myc标签cDNA稳定转染MDCK1细胞,挑选单克隆进行免疫细胞化学表征和125I-TRIAC转运活性生化表征。
主要发现
- 鉴定SLC22A9和SLC29A2为介导TRIAC细胞摄取的转运体;SLC22A9编码有机阴离子转运体7(OAT7),一种钠非依赖性有机阴离子转运体,表达于脑、垂体、肝脏等器官的质膜。
- 与SLC22A9/OAT7底物雌酮-3-硫酸酯竞争降低125I-TRIAC摄取;与SLC29A2/ENT2抑制剂硝基苄基-6-硫代肌苷共孵育降低125I-TRIAC摄取。
- ABCD1,一种ATP依赖性过氧化物酶体泵,在转染MDCK1细胞中被鉴定为125I-TRIAC外排泵。
局限性
- ABCD1的鉴定凸显了所建立筛选方法的敏感性,但可能对接受TRIAC治疗的患者不具有显著相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: 3,5,3'-Triiodothyroacetic acid (TRIAC) is a T3-receptor agonist pharmacologically used in patients to mitigate T3 resistance. It is additionally explored to treat some symptoms of patients with inactivating mutations in the thyroid hormone (TH) transporter monocarboxylate transporter 8 (MCT8, SLC16A2). MCT8 is expressed along the blood-brain barrier, on neurons, astrocytes, and oligodendrocytes. Hence, pathogenic variants in MCT8 limit the access of TH into and their functions within the brain. TRIAC was shown to enter the brain independently of MCT8 and to modulate expression of TH-dependent genes. The aim of the study was to identify transporters that facilitate TRIAC uptake into cells. Methods: We performed a whole-genome RNAi screen in HepG2 cells stably expressing a T3-receptor-dependent luciferase reporter gene. Validation of hits from the primary and confirmatory secondary screen involved a counter screen with siRNAs and compared the cellular response to TRIAC to the effect of T3, in order to exclude siRNAs targeting the gene expression machinery. MDCK1 cells were stably transfected with cDNA encoding C-terminally myc-tagged versions of the identified TRIAC-preferring transporters. Several individual clones were selected after immunocytochemical characterization for biochemical characterization of their 125I-TRIAC transport activities. Results: We identified SLC22A9 and SLC29A2 as transporters mediating cellular uptake of TRIAC. SLC22A9 encodes the organic anion transporter 7 (OAT7), a sodium-independent organic anion transporter expressed in the plasma membrane in brain, pituitary, liver, and other organs. Competition with the SLC22A9/OAT7 substrate estrone-3-sulfate reduced 125I-TRIAC uptake. SLC29A2 encodes the equilibrative nucleoside transporter 2 (ENT2), which is ubiquitously expressed, including pituitary and brain. Coincubation with the SLC29A2/ENT2 inhibitor nitrobenzyl-6-thioinosine reduced 125I-TRIAC uptake. Moreover, ABCD1, an ATP-dependent peroxisomal pump, was identified as a 125I-TRIAC exporter in transfected MDCK1 cells. Conclusions: Knowledge of TRIAC transporter expression patterns, also during brain development, may thus in the future help to interpret observations on TRIAC effects, as well as understand why TRIAC may not show a desirable effect on cells or organs not expressing appropriate transporters. The identification of ABCD1 highlights the sensitivity of our established screening assay, but it may not hold significant relevance for patients undergoing TRIAC treatment.
引用
- Becker PC, Güth-Steffens M, Lazarow K, et al. Identification of Human TRIAC Transmembrane Transporters. Thyroid. 2024. PMID: 38801167. doi:10.1089/thy.2023.0592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。